HOME >> MEDICINE >> NEWS
Identification Of Brain Areas Could Help Eliminate Side Effects Of Pain Medication

HERSHEY, Pa. --- Researchers at Penn State's College of Medicine have identified a set of neurons in the brain that may contribute to some of the undesirable side effects of pain medication.

"Opioids such as morphine and morphine-like drugs still comprise the major tool for the clinical management of pain even though the drugs can have some very serious side effects," explains Ralph Lydic, Ph.D., professor of anesthesia. "This discovery means we have specifically targeted an area in the brain and a molecule that causes side effects from pain medication. We want to try and eliminate these side effects of pain medication by building another molecule to tag onto the opioid molecule. This way the opioid could block the pain, and this new molecule could prevent the side effects."

Specifically, Lydic and his team have discovered that this set of neurons may account for morphine's ability to decrease brain production of acetylcholine, a chemical known to be essential for normal rapid eye movement (REM) sleep. Often after surgery, patients have disrupted REM sleep because of pain medication. Lydic explains that REM sleep is the dreaming phase of sleep and is essential for feeling rested. Everyone has REM sleep each night, even if we do not remember our dreams. REM sleep occurs about every 90 minutes and lasts for about 20 minutes.

"We think this is a very exciting discovery. We are trying to identify specific cells in the brain where we know brain-produced chemicals have been altered because of the pain medication administered," explains Lydic. Other common side effects from pain medications can include respiratory depression, itching, constipation, urinary retention and addiction.

The Penn State researcher says the team is trying to understand brain mechanisms that regulate consciousness as they try to improve pain control and anesthesia safety. He adds, "The discovery of anesthesia is onl
'"/>

Contact: Leilyn Perri
lperri@psghs.edu
717-531-8604
Penn State
8-May-1998


Page: 1 2

Related medicine news :

1. Brain activity prior to treatment flags vulnerability to antidepressant side effects
2. Brain imaging study may hold clues to onset of schizophrenia in people at high risk
3. Brain imaging reveals secrets of love, fear and betrayal
4. Brain imaging studies investigate pain reduction by hypnosis
5. Brain tumor with dismal prognosis in infants can be cured in older children
6. Brain-scanning technologies need standards, according to Stanford researcher
7. Brain activity of men and women during hostile or impulsive acts differs less on nicotine
8. Brain synapse formation linked to proteins, Stanford study finds
9. Brain tumor treatment can vary greatly, according to new JAMA study
10. Brain region identified that controls collecting behavior
11. Brain imaging reveals new language circuits

Post Your Comments:
(Date:5/21/2013)... An attack on glioblastoma brain tumor cells that ... an early study to establish the proper dose level, ... developed at Duke and tested in an ongoing phase ... have an abundance of receptors that work like magnets ... cells. , The investigational therapy, known as PVSRIPO, ...
(Date:5/21/2013)... Adeptia, a leading provider of innovative cloud ... is the featured company in an impact report written ... “Adeptia Bets on Converged Cloud Integration and Process-Orchestration Suites,” ... products, pricing, customers and competition. , “For ... integration and process orchestration, especially when price, ease of ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... some of the changes brought about by the disorder ... New research has found that people with diabetes who ... risk of having a severe low blood sugar (hypoglycemia) ... people with diabetes who aren,t depressed. "Depression ...
(Date:5/21/2013)... Grapefruits have long been known for their ... how medical therapies like anti-cancer drugs are delivered ... researchers have uncovered how to create nanoparticles using ... how to use them as drug delivery vehicles. ... Ph.D., and their team today (May 21, 2013), ...
(Date:5/21/2013)... May 21, 2013 Benefit Express Services, ... medium, and small organizations, will be hosting a free ... team from Findley Davies. The presentation will focus on ... in compliance with new Health Care Reform Requirements. The ... employees. , “Benefit Express regularly hosts free educational ...
Breaking Medicine News(10 mins):Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2Health News:Adeptia Featured in Recent 451 Research Impact Report 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Benefit Express to Host Workplace Wellness Webinar 2
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
(Date:5/21/2013)... 2013  BioRestorative Therapies, Inc. ("BRT" or the "Company") ... developing stem cell based therapies for various personal applications, ... President and CEO, will be presenting at the Marcum ... held on Thursday, May 30, 2013 at the Grand ... New York City.  Mr. Weinreb,s presentation will take place ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
Cached News: